These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 27810693)

  • 1. Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors.
    Bošković L; Gašparić M; Petković M; Gugić D; Lovasić IB; Soldić Ž; Miše BP; Dabelić N; Vazdar L; Vrdoljak E
    Breast; 2017 Feb; 31():16-19. PubMed ID: 27810693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of osteoporosis after breast cancer.
    Reid DM
    Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
    Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
    Tang SC
    Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical guidance for the management of aromatase inhibitor-associated bone loss.
    Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M
    Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience.
    Tremblay D; Patel V; Fifer KM; Caro J; Kolodka O; Mandelli J; Shapiro CL
    Support Care Cancer; 2018 Jan; 26(1):197-202. PubMed ID: 28744736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
    Gibson K; O'Bryant CL
    J Oncol Pharm Pract; 2008 Sep; 14(3):139-45. PubMed ID: 18719068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
    Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
    J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
    Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
    Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
    Bouvard B; Chatelais J; Soulié P; Hoppé E; Saulnier P; Capitain O; Mege M; Mesgouez-Nebout N; Jadaud E; Abadie-Lacourtoisie S; Campone M; Legrand E
    Eur J Cancer; 2018 Sep; 101():87-94. PubMed ID: 30036740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer and osteoporosis.
    Cheung AM; Heisey R; Srighanthan J
    Curr Opin Endocrinol Diabetes Obes; 2013 Dec; 20(6):532-8. PubMed ID: 24468755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
    Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
    Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial.
    Kilbreath S; Refshauge KM; Beith J; Ward L; Sawkins K; Paterson R; Clifton-Bligh P; Sambrook PN; Simpson JM; Nery L
    Contemp Clin Trials; 2011 Sep; 32(5):704-9. PubMed ID: 21570487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
    Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
    Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AI-related BMD variation in actual practice conditions: A prospective cohort study.
    Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Garcia-Giralt N; Garrigos L; Rodriguez-Morera J; Albanell J; Martínez-García M; González I; Diez-Perez A; Tusquets I; Nogués X
    Endocr Relat Cancer; 2016 Apr; 23(4):303-12. PubMed ID: 26911377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
    Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of calcium supplements, vitamin D supplements and specific osteoporosis drugs among French women aged 75-85 years: patterns of use and associated factors.
    Castro-Lionard K; Dargent-Molina P; Fermanian C; Gonthier R; Cassou B
    Drugs Aging; 2013 Dec; 30(12):1029-38. PubMed ID: 24114665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.